Category Archives: Clinical Cardiology

Topline data presented at AAN annual meeting showed AOC 1001 achieved directional improvements in multiple functional endpoint assessments - myotonia (vHOT), measures of strength (total QMT) and mobility (10mWRT, Timed Up and Go) AOC 1001 data demonstrate favorable safety/tolerability profile with most adverse events mild or moderate Topline AOC 1001 data identify dose range for pivotal study; Avidity continues to work to resolve partial clinical hold Volume 7 of investor and analyst event today at 5:30 p.m. ET in Boston and via webcast SAN DIEGO, April 27, 2023 /PRNewswire/ -- Avidity Biosciences, Inc Continue reading →

BARCELONA, SpainReal-world data on a new pulsed-field catheter ablation system for the treatment of atrial fibrillation (AF) suggest that roughly four out of every five patients will be free from AF, atrial flutter (AFL), or atrial tachycardia (AT) at 1 year. Clinical outcomes were better in those with paroxysmal rather than persistent AF, but use of the Farapulse pulsed-field ablation system (Boston Scientific) was safe in the overall cohort, with investigators observing no esophageal damage or pulmonary vein (PV) stenosis in this large, unselected patient population. Vivek Reddy, MD (Icahn School of Medicine at Mount Sinai, New York, NY), who presented the results of the MANIFEST-PF registry during a late-breaking clinical trial session at the European Heart Rhythm Association (EHRA) 2023 meeting last week, said there are several limitations to the new retrospective study. Continue reading →

Increasing use of genetic testing means people may discover they have a gene variant associated with some types of cardiovascular disease (CVD). Continue reading →

Older patients enrolled in the ISCHEMIA trial saw their angina symptoms improve with an invasive strategy as compared with more-conservative management, but unlike younger patients in the trial, they did not report the same improvements in overall health status, according to a new analysis. As with the overall trial, older patients did not have any improvement in hard clinical outcomes with an invasive approach, Dan Nguyen, MD (Saint Lukes Mid America Heart Institute, Kansas City, MO), and colleagues report in the Journal of the American College of Cardiology. Older adults represent the fastest growing population of patients in the United States, and stable ischemic heart disease is extremely common in this subset, Nguyen observed. Continue reading →

BARCELONA, SpainThe European Heart Rhythm Society (EHRA) has released a new consensus statement on conduction system pacing (CSP), which includes both His-bundle and left bundle branch (LBB) pacing, with the aim of standardizing the implantation technique and providing some direction for physicians looking to perform the procedure. The statement, which has been in the works for the past year, is intended as a practical, hands-on document for implanters looking for up-to-date guidance, according to lead author Haran Burri, MD (University Hospital of Geneva, Switzerland). In recent years, theres been an increase in CSP implantation, which has emerged as an alternative to RV pacing, as the procedure moves more into mainstream clinical practice. Continue reading →

DUBLIN, April 27, 2023 /PRNewswire/ --The "Artificial Intelligence/Machine Learning Medical Device Market - A Global and Regional Analysis: Focus on Product Type, Clinical Area, and Country Analysis - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering. Continue reading →

Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to participate in a national clinical trial that includes Memorial Cardiac and Vascular Institute and will determine whether a minimally-invasive valve replacement benefits those who are currently treated only with medication. HOLLYWOOD, Fla., Aug. 18, 2022 /PRNewswire-PRWeb/ -- Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to participate in a clinical trial that will determine whether a minimally-invasive valve replacement benefits those who are currently treated only with medication. Continue reading →

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from the landmark REDUCE-IT cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology (ESC) Congress, both online and onsite in Barcelona, August 26-29, 2022. The accepted abstracts include a Late-Breaking Science presentation on reduction of ST-segment Elevation MI with VASCEPA from the REDUCE-IT trial Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. Continue reading →

August 18, 2022 A first-in-human multicenter trial involvingMayo Clinicused a new ablation technique for patients withventricular tachycardia, an abnormally rapid heart rhythm that is a leading cause ofsudden cardiac deathworldwide. The trial tested needle ablation using in-catheter, heated, saline-enhanced, radio frequency energy, also known asSERF, to substantially increase heat transfer, compared to conventional ablation methods Continue reading →